Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Poster session 10

602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer

Date

21 Oct 2023

Session

Poster session 10

Topics

Clinical Research; Cytotoxic Therapy; Radiological Imaging; Radiation Oncology; Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Diogo Bugano Diniz Gomes

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

D. Bugano Diniz Gomes¹, V.M. Santos¹, A. Campos Bragagnoli², O. Barbosa Neto³, I.T. Carvalho⁴, J. Karassawa Helito³, C.D. Ortega¹, C. Franco Tridente¹, M. Novaes Figueiredo de Araújo¹, R.V. Pandini⁵, V.E. Seid⁵, A.S. POrtilho⁵, J.M. Melo¹, P. Blasi⁶, A. Buosso³, F. Rolla⁶, G. Schettino⁶, S.E.A. Araujo⁶

Author affiliations

¹ Medical Oncology, Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, 05653-120 - Sao Paulo/BR
² Gi Cancer, Hospital de Amor (Hospital De Cancer De Barretos) - Fundacao Pio XII, 14784-400 - Barretos/BR
³ Radiation Oncolgy, Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, 05653-120 - Sao Paulo/BR
⁴ Radiation Oncology, Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, 05653-120 - Sao Paulo/BR
⁵ Coloprocotology Department, Albert Einstein Israelite Hospital, 05652-900 - Sao Paulo/BR
⁶ Oncology Department, Albert Einstein Israelite Hospital, 05652-900 - Sao Paulo/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 602P

Background

Neoadjuvant radiation and oxaliplatin-based systemic therapy (Total Neoadjuvant Therapy – TNT) has been shown to increase response and organ-preservation rates in localized rectal cancer. However, trials have been heterogeneous regarding treatment protocols and few have used a watch-and-wait (WW) approach for complete responders. This trial evaluates if conventional long-term chemoradiation followed by consolidation FOLFIRINOX increases complete response rates and number of patients managed by WW.

Methods

Thiswas apragmatic randomized phase II trial conducted in 2 Cancer Centers in Brazil that included patients with T3+ or N+ rectal adenocarcioma. After completing long-course 54Gy chemoradiation with capecitabine patients were randomized 1:1 to observation or 4 cycles of mFOLFIRINOX (Oxaliplatin 85, irinotecan 135, 5-FU 2400). All patients were re-staged with dedicated pelvic MRI and sigmoidoscopy 12 weeks after the end of radiation. Patients with a clinical complete response were followed using a WW protocol. Primary enpoint was complete response: complete clinical response (cCR) or pathological response(pCR).

Results

Between Feb 2020 and April 2023, 46 patients were randomized to TNT and 42 to standard of care. Median age was 59 and 64% were male. Tumors were 68% stage 3, median distance from anal verge was 5cm, 43% had at-risk circumferential margin and 21% involved sphincter. The rates of cCR+pCR were 9/46 (19%) for TNT vs 5/42 (11%) for controls (OR 1.79, CI95% 0.54-6.3 p=0.16) and rates of WW were 5/46 (10.8%) and 2/45 (4%) (ns). Median follow-up was 16.9 months and recurrence rates were 8/46 (17%) and 11/42 (26%) for TNT and controls (ns).

Conclusions

TNT with consolidation FOLFIRINOX is feasible and has high response rates. Complete data from 96 patients will be presented at the meeting. This trial was supported by a grant from the Brazilian Ministry of Health (PROADI-SUS) - NUP 25000.164382/2020-81.

Clinical trial identification

NCT05081687.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Brazilian Ministry of Health - "PROADI-SUS".

Disclosure

All authors have declared no conflicts of interest.